| Followers | 43 |
| Posts | 4765 |
| Boards Moderated | 3 |
| Alias Born | 04/14/2008 |
Wednesday, May 26, 2010 10:21:08 PM
forward selling is where you sell all or an interest in a product that you don't yet have - what the two parties would do, if interested, is try to establish a value, and then start dinging it for risk of not receiving it, time it would take to get it, etc.
if you honestly think ONE of them is worth 300MM then it should be fairly easy to sell a 20% interest in one for 5-10MM bucks -
but to indicate that just because something's never been done before is reason enough to take the route chosen is disappointing -
there is a long, long history of screwy financings to companies of this type - to simply take the terms laying down was not righteous if all is what it is made out to be -
seymour probably needed better advisors in the deal - he did not get 500k worth of quality from the fees he paid the middle man -
if you honestly think ONE of them is worth 300MM then it should be fairly easy to sell a 20% interest in one for 5-10MM bucks -
but to indicate that just because something's never been done before is reason enough to take the route chosen is disappointing -
there is a long, long history of screwy financings to companies of this type - to simply take the terms laying down was not righteous if all is what it is made out to be -
seymour probably needed better advisors in the deal - he did not get 500k worth of quality from the fees he paid the middle man -
Bernie Madoff [with my money]
a haiku by uncle soy
gray-haired bandido,
the target of grumpiness,
where's the benjamins?
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
